TerminatedNCT00211562
Adjunctive Supplementation of Antioxidants (Vitamins E + C) Plus Omega-3 Fatty Acids
Medication studyAges 18–55United StatesSchizophrenia
Understand this study
Who could participate?
Listed age limits: 18 years to 55 years.
- Listed locations
- AugustaSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateOctober 2005
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 20
- Sponsor
- Augusta University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT00211562
- Official title
Show the full official title
Reduction of Body Weight in Olanzapine Treated Schizophrenia Patients by Adjunctive Supplementation of Antioxidants (Vitamins E + C) Plus Omega-3 Fatty Acids
Recruitment & locations
TerminatedAugusta
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Augusta University, a university.
Does this study involve medication?
Yes. The study involves medication, including Olanzapine, Omega 3, Vitamin E+C.
Who can participate?
Listed age limits: 18 years to 55 years.
Is this study still recruiting?
The registry lists this study as terminated.
Want to explore more studies?
Explore studiesRelated studies
20101299: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms
20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms (Study 165)